南华生物
(000504)
| 流通市值：38.70亿 | | | 总市值：38.81亿 |
| 流通股本：3.29亿 | | | 总股本：3.30亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 295,914,290.97 | 119,301,354.8 | 415,939,732.49 | 83,438,454.98 |
| 营业总成本 | 299,810,787.12 | 109,875,018.81 | 403,227,245.62 | 87,427,614.24 |
| 其他经营收益 | | | | |
| 营业利润 | -1,985,047.65 | 11,608,592.49 | 20,047,873.47 | -2,481,176.1 |
| 利润总额 | -2,044,447.8 | 11,547,433.94 | 19,722,611.54 | -3,111,035.68 |
| 净利润 | 865,013.31 | 11,075,848.68 | 18,052,280.09 | -3,149,584.02 |
| 每股收益 | | | | |
| 其他综合收益 | - | - | - | - |
| 综合收益总额 | 865,013.31 | 11,075,848.68 | 18,052,280.09 | -3,149,584.02 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 632,214,609.22 | 767,056,212.74 | 738,919,808.02 | 517,436,883.8 |
| 非流动资产: | | | | |
| 非流动资产合计 | 249,018,410.18 | 249,367,880.73 | 252,811,195.74 | 324,519,091.72 |
| 资产总计 | 881,233,019.4 | 1,016,424,093.47 | 991,731,003.76 | 841,955,975.52 |
| 流动负债: | | | | |
| 流动负债合计 | 434,615,720.02 | 554,765,494.13 | 545,155,346.41 | 364,357,911.84 |
| 非流动负债: | | | | |
| 非流动负债合计 | 87,755,964.61 | 92,586,429.18 | 89,069,335.89 | 114,942,076.06 |
| 负债合计 | 522,371,684.63 | 647,351,923.31 | 634,224,682.3 | 479,299,987.9 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 271,743,864.95 | 276,851,852.62 | 265,751,170.73 | 242,327,514.63 |
| 股东权益合计 | 358,861,334.77 | 369,072,170.16 | 357,506,321.46 | 362,655,987.62 |
| 负债和股东权益合计 | 881,233,019.4 | 1,016,424,093.47 | 991,731,003.76 | 841,955,975.52 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 499,004,875.59 | 135,032,175.53 | 300,072,947.41 | 137,634,484.38 |
| 经营活动现金流出小计 | 504,964,762.73 | 225,733,992.05 | 415,808,294.92 | 120,309,599.44 |
| 经营活动产生的现金流量净额 | -5,959,887.14 | -90,701,816.52 | -115,735,347.51 | 17,324,884.94 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 889,817,761.19 | 336,577,580.39 | 282,097,506.71 | 110,346,204.21 |
| 投资活动现金流出小计 | 896,274,809.51 | 458,792,558 | 255,212,232.87 | 167,039,408.23 |
| 投资活动产生的现金流量净额 | -6,457,048.32 | -122,214,977.61 | 26,885,273.84 | -56,693,204.02 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 86,750,000 | 56,123,571.2 | 270,261,744.13 | 1,250,000 |
| 筹资活动现金流出小计 | 112,132,522.96 | 6,597,388.97 | 41,979,730.98 | 6,594,267.76 |
| 筹资活动产生的现金流量净额 | -25,382,522.96 | 49,526,182.23 | 228,282,013.15 | -5,344,267.76 |
| 汇率变动对现金及现金等价物的影响 | -83.67 | - | -61.29 | -11.45 |
| 现金及现金等价物净增加额 | -37,799,542.09 | -163,390,611.9 | 139,431,878.19 | -44,712,598.29 |
| 期末现金及现金等价物余额 | 308,965,483.03 | 183,374,413.22 | 346,765,025.12 | 162,620,548.64 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | -37,799,542.09 | - | 139,431,878.19 | - |